BioFocus and Activiomics have formed a partnership,which will enable BioFocus to offer its customers Activiomics' proteomics services to improve identification of new targets for drug discovery and biomarkers for diagnostics.
TIQUAS (Targeted In-depth QUAntification of cell Signaling), Activiomics' proprietary technology, offers insight into which proteins or pathways have been activated following a cell signaling event.
The technology uses mass spectroscopy based techniques to detect and quantify thousands of phosphorylation sites from a cell/tissue extract.
TIQUAS is used in therapeutic areas, which include oncology, inflammation and metabolic disease.
BioFocus Galapagos Services senior vice president and managing director Chris Newton said Proteomics analysis, in particular phosphoproteomics, is becoming ever more important in drug discovery programs.
''By partnering with Activiomics, BioFocus extends its offering of high-quality scientific expertise into this newly emerging area," Newton added.
Activiomics CEO Mark Warne said the company is delighted to begin the partnership with BioFocus.
''We are looking forward to making our popular platform even more widely available through exposure to BioFocus' large and growing client base,"Warne added.